AMPH vs Peers Stock Comparison

Amphastar Pharmaceuticals Prices as of Oct 26, 2026 Peers: Industry group

Percentile Scorecard

AMPH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMPH
Valuation 97 #8 of 275
Growth 43 #144 of 253
Profitability 87 #29 of 224
Financial Health 42 #171 of 296
Shareholder Returns 99 #2 of 126
Overall 74
  • AMPH ranked among 305 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMPHSPY
1 month -2.5% -0.8%
3 months +32.8% +3.5%
6 months +17.6% +7.0%
Year to date -4.9% +12.2%
1 year +3.9% +13.0%
3 years -42.9% +86.3%
3 years, per year -17.1% +23.1%
5 years +38.7% +68.6%
5 years, per year +6.8% +11.0%
10 years +40.1% +258.0%
10 years, per year +3.4% +13.6%

Risk

MeasureAMPHSPY
Volatility, 1Y 54.3% 12.7%
Downside volatility, 1Y 66.4% 12.7%
Beta vs S&P 500, 1Y 0.58 1.00
Return / volatility, 1Y 0.07 1.02
Max drawdown, 5Y -74.0% -25.4%
From 52-week high -13.4% -1.8%
52-week high $29.40 $779.14
52-week low $16.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMPH
P/E now vs peer median 14.2xmedian 10.4x
P/S now vs peer median 1.5xmedian 6.4x
EV/EBITDA now vs peer median 8.0xmedian 10.7x
P/FCF now vs peer median 7.1xmedian 12.5x
P/B now vs peer median 1.4xmedian 1.6x
PEG now vs peer median -5.53median 0.29

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMPH
Revenue $730.02M
Gross profit $348.11M
Operating income $114.29M
Net income $78.55M
Free cash flow $152.89M
R&D $94.57M
EPS (diluted) $1.78
Cash & equivalents $223.61M
Total debt $612.05M
Shares (diluted) 44.23M
Enterprise value -$57.80M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMPH
P/E 14.2x
P/FCF 7.1x
P/Operating cash flow 5.9x
P/S 1.5x
P/B 1.4x
P/Tangible book 1.5x
EV/EBITDA 8.0x
EV/EBIT 12.3x
EV/Revenue 1.9x
EV/FCF 9.2x
EV/Operating cash flow 7.6x
PEG (3Y EPS CAGR) -5.53

Growth

14 metrics
MetricAMPH
Revenue growth (1Y) 1.0%
Revenue CAGR (3Y) 10.5%
Gross profit growth (1Y) -3.4%
Gross profit CAGR (3Y) 8.0%
Operating income growth (1Y) -37.1%
Operating income CAGR (3Y) -4.5%
Net income growth (1Y) -41.7%
Net income CAGR (3Y) -8.3%
EPS growth (1Y) -36.5%
EPS CAGR (3Y) -2.6%
Operating cash flow growth (1Y) 15.6%
Operating cash flow CAGR (3Y) 12.1%
Free cash flow growth (1Y) 36.3%
Free cash flow CAGR (3Y) 15.0%

Profitability

14 metrics
MetricAMPH
Gross margin 47.7%
EBITDA margin 23.9%
Operating margin 15.7%
Pretax margin 14.0%
Net margin 10.8%
FCF margin 20.9%
Operating cash flow margin 25.3%
Return on equity 10.2%
Return on assets 4.6%
Return on invested capital 6.4%
Return on capital employed 8.0%
Asset turnover 0.4x
Cash conversion (OCF / net income) 2.4x
Stock comp / revenue 4.0%

Financial Health

11 metrics
MetricAMPH
Debt / assets 35.1%
Debt / equity 0.8x
Net debt / EBITDA 1.8x
Debt / FCF 4.0x
Liabilities / assets 55.9%
Equity / assets 44.1%
Interest coverage 4.4x
Current ratio 2.4x
Quick ratio 1.7x
Cash ratio 1.1x
Altman Z-score 2.12

Shareholder Returns

7 metrics
MetricAMPH
Dividend yield –
Net buyback yield 9.0%
Shareholder yield 9.0%
Payout ratio (earnings) –
Payout ratio (FCF) –
Dividend growth (1Y) –
Dividend CAGR (3Y) –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMPH
Forward P/E 8.2xFY2026
EPS, next fiscal year $3.10FY2026
EPS growth, next FY -4.6%FY2026
EPS growth, the year after +9.4%
Revenue, next fiscal year $790.75MFY2026
Revenue growth, next FY +9.8%FY2026
Revenue growth, the year after -5.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMPH
Held by institutions 64.8%
Institutions holding 209
Change in shares held, QoQ -11.7%
Institutions buying 96
Institutions selling 74
Buyers to sellers 1.30

Add a Peer

Largest companies in the same industry

Related Comparisons

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.